Baidu
map

Nat Genet:结核病研究取得新进展

2013-09-03 张章 中国科学报

数个独立研究团队为来自世界不同地区的结核分枝杆菌进行了全基因组测序,成果于9月2日发表在《自然—遗传学》期刊上。相关研究有望为耐药性结核病疫情的出现提供新见解,并为耐药性测试和药物开发提供新标靶。【原文下载】 美国马萨诸塞州总医院教授Maha Farhat领衔的研究小组,为全球123种具有代表性的结核分枝杆菌菌株(包括耐药性菌株)进行了全基因组测序和分析。该研究小组借鉴了菌株之

数个独立研究团队为来自世界不同地区的结核分枝杆菌进行了全基因组测序,成果于9月2日发表在《自然—遗传学》期刊上。相关研究有望为耐药性结核病疫情的出现提供新见解,并为耐药性测试和药物开发提供新标靶。【原文下载

美国马萨诸塞州总医院教授Maha Farhat领衔的研究小组,为全球123种具有代表性的结核分枝杆菌菌株(包括耐药性菌株)进行了全基因组测序和分析。该研究小组借鉴了菌株之间的进化关系,开发出一种在微生物基因组中搜寻耐药性标记的新方法,并在结核分枝杆菌的基因组中确认了39个与耐药性有关的基因组区段。

来自美国新泽西医学院的David Alland教授与其研究团队,为渗入了一线抗结核药乙胺丁醇的结核分枝杆菌菌株进行了基因组测序,并在63个临床菌株中找到与研究结果相关的发现。他们的功能研究为一个多步骤、包含了基因突变相互作用的乙胺丁醇耐药模型提供了支持理据。

最后,西班牙公共健康研究中心教授Inaki Comas及其同事分析了259个结核分枝杆菌菌株复合体基因组序列,为这种病菌的遗传多样性和与人类宿主一起的进化过程提供了见解。分析结果显示,分枝杆菌菌株复合体约70万年前在非洲出现,然后随人类迁徙而蔓延出非洲。

原文下载

Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, Jacobson KR, Victor TC, Warren RM, Streicher EM, Calver A, Sloutsky A, Kaur D, Posey JE, Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, Rodrigues M, Tang PK, Kato-Maeda M, Borowsky ML, Muddukrishna B, Kreiswirth BN, Kurepina N, Galagan J, Gagneux S, Birren B, Rubin EJ, Lander ES, Sabeti PC, Murray M.Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis.Nat Genet. 2013 Sep 1. 

    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733648, encodeId=74d61e3364826, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jan 29 12:13:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048526, encodeId=feec2048526de, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 01 16:13:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685905, encodeId=823716859059c, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Feb 08 05:13:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253882, encodeId=604a125388261, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Sep 05 04:13:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879654, encodeId=902718e965449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 25 17:13:00 CST 2014, time=2014-02-25, status=1, ipAttribution=)]
    2014-01-29 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733648, encodeId=74d61e3364826, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jan 29 12:13:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048526, encodeId=feec2048526de, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 01 16:13:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685905, encodeId=823716859059c, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Feb 08 05:13:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253882, encodeId=604a125388261, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Sep 05 04:13:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879654, encodeId=902718e965449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 25 17:13:00 CST 2014, time=2014-02-25, status=1, ipAttribution=)]
    2013-11-01 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733648, encodeId=74d61e3364826, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jan 29 12:13:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048526, encodeId=feec2048526de, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 01 16:13:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685905, encodeId=823716859059c, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Feb 08 05:13:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253882, encodeId=604a125388261, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Sep 05 04:13:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879654, encodeId=902718e965449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 25 17:13:00 CST 2014, time=2014-02-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733648, encodeId=74d61e3364826, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jan 29 12:13:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048526, encodeId=feec2048526de, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 01 16:13:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685905, encodeId=823716859059c, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Feb 08 05:13:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253882, encodeId=604a125388261, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Sep 05 04:13:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879654, encodeId=902718e965449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 25 17:13:00 CST 2014, time=2014-02-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1733648, encodeId=74d61e3364826, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Jan 29 12:13:00 CST 2014, time=2014-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048526, encodeId=feec2048526de, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Nov 01 16:13:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685905, encodeId=823716859059c, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Feb 08 05:13:00 CST 2014, time=2014-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253882, encodeId=604a125388261, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Thu Sep 05 04:13:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879654, encodeId=902718e965449, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Feb 25 17:13:00 CST 2014, time=2014-02-25, status=1, ipAttribution=)]
    2014-02-25 liye789132251

相关资讯

空气污染增加肺部疾病发生率

  “结核病离我们并不遥远,每年约有5万人死于结核病,相当于每10分钟就有1人死亡。”这个数字出自3月24日第十八个世界肺结核日。据估算,我国每年新发结核病人100万,一些地区的结核病甚至出现了上涨的苗头。   “近年来我国肺结核的发病率并没有明显下降。”解放军总医院呼吸科刘又宁教授告诉《生命时报》记者,结核病依然是目前危害国人健康的最重要传染病。过去它是一种“贫困病”,如今很多生活条件好的人也

Nucleic Acids Res:MfpB基因可能是结核分枝杆菌药物抗性的机制

结核病是由结核分枝杆菌引起的人类慢性传染性疾病,是导致人类死亡最多的传染病之一,并且全球约有1/3人口为结核分枝杆菌感染者。我国是全世界22个结核病高负担国家之一,感染人数超过4亿,每年新发传染性病人150万,约有13万人死于结核病。新近的统计数据显示大于10%的病例至少对一种药物有抗性,1%病例为多耐药菌感染,在某些地方已经分离出目前尚无药可治的结核分枝杆菌耐药菌株。因此研究结核分枝杆菌抗药机制

APJCP:IL-21联合CEA可提高恶性胸腔积液诊断率

胸腔积液是许多疾病胸膜受累的常见表现,但是如何区分结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)一直是困扰临床医生的难题。针对这种情况,来自华中科技大学同济医学院卫生部肺疾病重点实验室的徐永健教授等等人进行了一项研究,研究结果在线发表于2012年第13卷第7期的《亚太癌症预防杂志》(Asian Pacific Journal of Cancer Prevention)杂志上。作者发现IL-2

Nat Chem Biol:解开结核病三十年的谜团

在三十年搜寻之后,一组抗肺结核化合物的随机筛选引导科学家到一个"尤里卡"发现,这个发现打破了保护细菌、允许细菌存活并持续对抗治疗的一个要塞。 美国科罗拉多州立大学的这两项发现发表在今天的Nature Chemical Biology上。文章描述了细菌中引起结核病的一个重要细胞功能的发现,这个细胞功能让细菌得以存活。研究人员也发现了一种阻止细胞这个功能的化合物。 很难杀死引起结核病的细菌,当今市

中国疾控中心与Aeras签署结核疫苗研发协议

在全球性结核病变得越来越难以治疗、成本越来越高以及致死性越来越强的情况之下,中国疾病预防控制中心(中国疾控中心)和Aeras今天签署了一项旨在推进新结核病疫苗研究和发展的谅解备忘录。新的结核病疫苗为根除这种每年导致全球140万人死亡的空气传播传染病带来了希望。 尽管中国在过去30年间结核病的发病和死亡数量均大幅减少,但结核病仍然是一个威胁公众健康的重大问题,每年在中国都有超过100万的新发病例。

Nat Med:合成抗菌分子Q203有望治疗耐药结核病

本周的Nature Medicine报道,一种新的药物能够抑制结核分枝杆菌生长,这一发现可能会提高治疗的耐药结核病(TB)的治疗选择。 世界三分之一人口受到结核分枝杆菌的潜伏感染,每年超过百万人死于结核病。耐多药结核分枝杆菌菌株已经广泛传播,因此,开发新的和改进的药物迫在眉睫。 韩国学者Kevin Pethe及其同事筛选了巨噬细胞中的结核分枝杆菌生长抑制剂的化学库,并确定imidazopyri

Baidu
map
Baidu
map
Baidu
map